Azria D, Auvray H, Barillot I, Baumann P, Benyoucef A, Bons-Rosset F, Bontemps P, Bourgier C, Breton-Callu C, Cowen D, Cretin J, Delalande B, Denis F, Ellis S, Gaci Z, Hannoun-Lévy J-M, Hasbini A, Hennequin C, Lagrange J-L, Lartigau E, Latorzeff I, Le Blanc-Onfroy M, Lecouillard I, Lemanski C, Levy C, Maingon P, Marchal C, Monnier A, Pradier O, Racadot S, Romestaing P, Serin D, Simon J-M, Teyssier E, Tallet A, Tolédano A, Belkacémi Y
Département de radiothérapie, CRLC Val d'Aurelle - Paul-Lamarque, rue Croix-Verte, 34298 Montpellier cedex 5, France.
Cancer Radiother. 2008 Nov;12(6-7):571-6. doi: 10.1016/j.canrad.2008.07.005. Epub 2008 Aug 13.
Ductal carcinoma in situ is defined as breast cancer confined to the ducts of the breast without evidence of penetration of the basement membrane. Local treatment quality represents one of the most prognostic factors as half of recurrences are invasive diseases. The main goal of adjuvant radiotherapy after conservative surgery is to decrease local recurrences and to permit breast conservation with low treatment-induced sequelae. Several randomized trials have established the impact of 50 Gy to the whole breast in terms of local control. Nevertheless, no randomized trial is still available concerning the role of the boost in this disease. In this review, we present updated results of the literature and we detail the French multicentric randomized trial evaluating the impact of a 16 Gy boost after 50 Gy delivered to the whole breast in 25 fractions and 33 days. This protocol will start inclusions in October 2008.
导管原位癌被定义为局限于乳腺导管内的乳腺癌，且无基底膜穿透的证据。局部治疗质量是最重要的预后因素之一，因为一半的复发是浸润性疾病。保乳手术后辅助放疗的主要目标是降低局部复发率，并在低治疗后遗症的情况下实现保乳。多项随机试验已证实全乳照射50 Gy对局部控制的影响。然而，关于加量照射在这种疾病中的作用，目前仍没有随机试验。在本综述中，我们展示了文献的最新结果，并详细介绍了法国多中心随机试验，该试验评估了在25次分割、33天内全乳照射50 Gy后加量照射16 Gy的影响。该方案将于2008年10月开始纳入患者。
